Up to 80% of patients with scleroderma have lung disease, with interstitial lung disease
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …

Objective We sought to determine the effectiveness of mycophenolate mofetil (MMF) in
scleroderma-associated interstitial lung disease (SSc-ILD). Methods We retrospectively …

Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However …

Objective. To report the efficacy and tolerability of mycophenolate mofetil (MMF) and
azathioprine (AZA) in the management of systemic sclerosis-associated interstitial lung …

Objective To compare mycophenolate mofetil (MMF) with placebo for the treatment of
systemic sclerosis (SSc)–related interstitial lung disease (ILD). Methods We included …

Background Interstitial lung disease (ILD) frequently complicates connective tissue diseases
(CTDs). Glucocorticoids and immunomodulatory agents are regarded as mainstays of …

Background Scleroderma is a systemic autoimmune disease characterized mainly by skin
manifestations and involvement of various visceral organs, especially the lungs. Lung …

This study aims to determine the effectiveness of mycophenolate sodium (MS) in patients
with scleroderma (SSc)-related interstitial lung disease (ILD). In a prospective observational …

To assess the effect of mycophenolate mofetil (MMF) on pulmonary functions in patients with
systemic sclerosis‐associated lung disease (SS c‐ILD) who experienced an inadequate …

Interstitial lung disease (ILD) is the leading cause of mortality in patients with systemic
sclerosis (SSc), which is also known as scleroderma. Two randomized clinical trials in …